Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

Belite Bio, Inc American Depositary Shares (BLTE)

https://www.belitebio.com

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/29/2022

Market Cap

1,526,944,467

Shares Outstanding

25,230,000

Weighted SO

27,599,244

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

Beta

-1.4780

Last Div

0.0000

Range

24.07-50.66

Chg

-0.0200

Avg Vol

54637

Mkt Cap

1526944467

Exch

NASDAQ

Country

Phone

858-246-6240

DCF Diff

46.5984

DCF

3.2816

Div Yield

0.0000

P/S

0.0000

EV Multiple

-41.4047

P/FV

15.6792

Div Yield %

0.0000

P/E

-42.8599

PEG

0.4662

Payout

0.0000

Current Ratio

0.0000

Quick Ratio

0.0000

Cash Ratio

0.0000

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

0.0000

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-0.0003

ROA

-0.3489

ROE

-0.4199

ROCE

-0.3630

NI/EBT

1.0002

EBT/EBIT

0.9610

EBIT/Rev

0.0000

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

0.0000

CF/Debt

0.0000

Equity Multi

1.0485

Rec Turnover

0.0000

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

0.0000

FCF/Share

0.0000

Cash/Share

3.1493

OCF/Sales

0.0000

FCF/OCF

0.0000

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

15.6792

P/B

15.6792

P/S

0.0000

P/E

-42.8599

P/FCF

0.0000

P/OCF

0.0000

P/CF

0.0000

PEG

0.4662

P/S

0.0000

EV Multiple

-41.4047

P/FV

15.6792

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 13, 00:00 International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 VIOT, CLCGY, HCM, COE, YRD, +6 more GlobeNewswire Inc. Feb 06, 03:35 Belite Bio Announces Registered Direct Offering of $15 Million BLTE GlobeNewswire Inc. Sep 04, 00:16 Belite Bio ????????Hendrik P. N. Scholl ??????? BLTE GlobeNewswire Inc. Sep 04, 00:16 Belite Bio ???? Hendrik P. N. Scholl ?????????? BLTE GlobeNewswire Inc. Sep 03, 23:00 ???????? (Belite Bio)????????P?N??????????? (Hendrik P. N. Scholl, MD, MA) ??????????????????? BLTE GlobeNewswire Inc. Jun 12, 06:55 Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan BLTE GlobeNewswire Inc. Nov 13, 20:15 Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results BLTE GlobeNewswire Inc. Nov 13, 20:15 Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results BLTE GlobeNewswire Inc. Nov 13, 20:15 Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results BLTE

Revenue Product Segmentation

Year	Purchases	Sales	Total Bought	Total Sold

Transaction Date	Name	Type Of Owner	Price	Securities Owned	Securities Transacted	Security Name	Transaction Type

Less Than 3 Months

0.00 Shares Bought (0 %)

0.00 Shares Sold (0%)

3 - 6 Months

0.00 Shares Bought (0 %)

0.00 Shares Sold (0%)

6 - 9 Months

0.00 Shares Bought (0 %)

0.00 Shares Sold (0%)

9 - 12 Months

0.00 Shares Bought (0 %)

0.00 Shares Sold (0 %)

Investor Name	Investment Discretion	Type of Security	Shares Owned	Avg Price Paid	Market Value	Change In Market Value	Change In Market Value (%)	Ownership	Weight

Date	Investors Holding	Closed Positions	Increased Positions	Reduced Positions	New Positions	Total Invested	Put/Call Ratio	Total Calls	Total Puts

Owner	Shares Owned

	2020	2021	2023	2024	2024	1970
Revenue	0.00	0.00	0.00	0.00	0.00
Cost Of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
Gross Profit Ratio	0.00	0.00	0.00	0.00	0.00	▼
Research And Development Expenses	922.00K	▲ 1.85M	▲ 5.23M	▼ 4.86M	▲ 6.77M	▼
General And Administrative Expenses	513.75K	▲ 594.50K	▲ 1.50M	▲ 2.09M	▼ 0.00
Selling And Marketing Expenses	0.00	0.00	0.00	0.00	0.00
Selling General And Administrative Expenses	513.75K	▲ 594.50K	▲ 1.50M	▲ 2.09M	▼ 1.56M	▼
Other Expenses	-2.87M	▲ 31.50K	▼ -70.00K	▼ -85.00K	▲ 0.00
Operating Expenses	-1.44M	▲ 2.48M	▲ 6.72M	▲ 6.96M	▲ 8.33M	▼
Cost And Expenses	1.44M	▲ 2.45M	▲ 6.72M	▲ 6.96M	▲ 8.33M	▼
Interest Income	0.00	0.00	▲ 4.00	▼ 0.00	0.00
Interest Expense	5.25K	▼ -32.75K	▲ 32.75K	▼ 0.00	0.00
Depreciation And Amortization	3.00K	▲ 32.75K	▼ -32.75K	▲ 34.75K	▼ 0.00
Ebitda	-1.43M	▼ -2.42M	▼ -6.53M	▼ -6.96M	▼ -8.33M	▼
Ebitda Ratio	0.00	0.00	0.00	0.00	0.00	▼
Operating Income	-1.44M	▼ -2.45M	▼ -6.72M	▼ -6.96M	▼ -8.33M	▼
Operating Income Ratio	0.00	0.00	0.00	0.00	0.00	▼
Total Other Income Expenses Net	-2.25K	▲ 32.75K	▼ -70.00K	▲ -36.00K	▲ 463.00K	▼
Income Before Tax	-1.44M	▼ -2.42M	▼ -6.78M	▼ -6.99M	▼ -7.87M	▼
Income Before Tax Ratio	0.00	0.00	0.00	0.00	0.00	▼
Income Tax Expense	250.00	▼ -32.75K	▲ 32.75K	▼ -1.00K	▲ 6.00K	▼
Net Income	-1.44M	▼ -2.38M	▼ -6.78M	▼ -6.99M	▼ -7.87M	▼
Net Income Ratio	0.00	0.00	0.00	0.00	0.00	▼
Eps	-0.06	▼ -0.10	▼ -10.44K	▲ -0.25	▼ -0.27	▼
Eps Diluted	-0.06	▼ -0.10	▼ -10.44K	▲ -0.25	▼ -0.27	▼
Weighted Average Shs Out	24.10M	24.10M	▼ 650.00	▲ 28.32M	▲ 29.68M	▼
Weighted Average Shs Out Dil	24.10M	24.10M	▼ 650.00	▲ 28.32M	▲ 29.68M	▼